MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel therapeutics for the treatment of pain in the United States. MAXONA is developing MAX-001 as the first novel therapeutic alternative to opioids and NSAIDs for the treatment of pain. While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAX-001 is an ex-US marketed non-opioid, non-NSAID analgesic New Molecular Entity which aims to fundamentally address the short-comings of existing therapies. MAXONA has assembled a highly experienced and well recognized management team with a proven record of successfully developing and commercializing effective therapeutics. We are committed to developing novel therapies for treating pain...without compromise.